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INTRODUCTION
Vagus nerve stimulation (VNS) 1 is an adjunctive nonpharmacological neurostimulatory approach for the treatment of patients with intractable epilepsy. VNS devices direct short bursts of electrical energy into the brain via the vagus nerve. The process is based primarily on the principle that high-frequency stimulation of the afferent vagus nerve produces EEG desynchronization, thereby interrupting the synchronized electrical activity seen in seizures [1] . Other proposed mechanisms for seizure inhibition through VNS include intensity-dependent changes in regional cerebral blood flow, an increase in gamma-aminobutyric acid (GABA) with a decrease in glutamate levels, upregulation of GABA A receptors, an increase in noradrenergic secretion via the locus coeruleus, and serotonergic transmission via the raphe magnus [2] . The use of VNS has progressively increased because of its promising results: a >50% reduction in seizure frequency in more than 50% of patients following implantation in both adults and children who have focal as well as generalized seizures [3, 4] .
VNS has also been suggested to cause significant weight loss (>5% of body weight) within 6-12 months of implantation and initiation of stimulation. The pathway for the cascade of metabolic and behavioral changes resulting in weight loss is through vagus nerve modulation from the gut to the brain, inducing hypometabolism of the hypothalamus and the consequent involvement of the satiety centers [5, 6] . Although VNS has been shown experimentally to affect eating behaviors, food cravings, and weight, these findings are inconsistent in humans using VNS therapy for either treatmentresistant epilepsy or depression. In a few studies, patients who received VNS therapy 1 VNS, vagus nerve stimulation; GABA, gamma-aminobutyric acid
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4 experienced significant weight loss, whereas in others, the treatment had no effect on weight [7] [8] [9] .
Our case report describes a middle-aged male patient who experienced substantial appetite suppression and subsequent weight loss with initiation of stimulation that resolved when stimulation was discontinued. With reintroduction of stimulation, the patient had no change in appetite, but positive seizure control continued.
CASE REPORT
A October 2010 while the patient was on antiseizure medications) was within normal limits.
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ACCEPTED MANUSCRIPT 5 We found no significant, pertinent abnormal findings on physical examination during his first visit. His follow-up laboratory values were within normal limits, including the antiseizure drug levels (levetricetam 39.9 mcg/ml) and TSH (2.2 mIU/L). His brain magnetic resonance imaging was abnormal, showing mild to moderate age-advanced cerebral and cerebellar atrophy, most likely to be an insult from hypoxic ischemic encephalopathy at birth. During the patient's follow-up period after his initial visit, he failed adjustments of levetiracetam (increase to 1,500 mg BID). Hence, we decided to proceed with VNS device implantation surgery for his intractable epilepsy. The precise mechanisms for VNS-induced weight loss are largely unknown. The vagus nerve forms the integral link between receptors in the proximal stomach, pylorus, and duodenum (mechano-, chemo-, osmo-, thermo-) and the satiety and feeding centers of the brain, located in the ventromedial hypothalamus and lateral hypothalamus, generating appropriate endocrine, metabolic, autonomic, and behavioral response to peripheral gastrointestinal events [12] . Hence, it is hypothesized that the disruption of this brain-gut axis would result in changes in metabolism, attenuation of the effects of cholecystokinin and leptin (satiety hormones), changes in hunger and/or satiety signaling in the brain, or changes in food cravings [13, 14] .
Studies of patients who received VNS therapy for the treatment of epilepsy have shown significant weight loss within 6-12 months of device implantation and with increasing stimulation parameters for seizure inhibition [9, 15, 16] . Our patient experienced a similar weight loss of 12% of his body weight (approximately 6 kg) within 6 months of VNS initiation, with standard stimulation parameters for seizure control of amplitude 0.25 mA, frequency 30 Hz, pulse width 500 μs, on-time 30 seconds, and offtime 5 minutes. His lowest weight while on VNS therapy was 41.6 kg, which was 7% above the ideal body weight for height (39 kg). Furthermore, studies have outlined a relationship between baseline BMI and VNS-related weight loss in which a tendency toward greater weight loss was observed in patients with higher BMIs [17] . We observed
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8 similar findings of weight loss proportional to initial BMI in our patient who had a relatively higher BMI based on height. .
However, inconsistencies exist among studies, questioning the effects of VNS on
weight loss and associations of baseline BMI with weight loss. Few studies showed that VNS did not lead to significant changes in body weight in patients with epilepsy [7, 18] .
A study of the effects of chronic VNS on caloric intake showed that lean individuals consumed fewer calories than those who were overweight or obese, affecting the BMI-VNS relationship [14] . The possible explanations for this scenario included development of a decreased craving for palatable foods, resistance to the satiating effects of leptin, and the alteration of vagal afferent pathways in patients with a history of overeating higher fat and caloric foods who are less likely to have food intake altered after VNS. Also, the location of stimulation along the vagal nerve course can differentially affect eating habits and weight loss. Studies propose that electrical blockade of vagal trunks at the level of the gastric cardia has a more pronounced impact on eating behavior and weight loss and is comparatively less diluted than stimulation of the vagus nerve in the cervical area [19] [20] [21] .
agus nerve stimulation (VNS) is a valuable treatment option for patients with intractable epilepsy. Evidence of disruption of brain-gut axis from VNS has extended its therapeutic capabilities to obesity management. We report a case of a middle-aged male treated with VNS for refractory epilepsy who, after experiencing substantial appetite suppression, throat irritation and subsequent weight loss with stimulation, developed desensitization to this response following a period of cessation. Despite reinitiating VNS
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9 with higher amplitude, he experienced steady weight gain which surpassed his baseline, in addition to effective seizure control. To our knowledge, similar cases have not been previously reported.
In our patient, we hypothesize two distinct potential mechanisms to be responsible for the weight loss. The first being a central mediated process effecting appetite as described in the literature above. The second being a peripheral effect of VNS on the throat leading to irritation and reduced oral intake in a patient with limited language skills (indirect mechanism). After the VNS-induced weight loss, very interestingly our patient developed desensitization to this effect on body weight. The later stimulation parameters were, in fact, higher than the initial parameters with no effect on weight. Our patient steadily regained the weight he had lost throughout the stimulation break period and through the period of reintroduction of stimulation. The cessation of stimulation for a period of 3 months may have reset the vagal tone. We postulate that vagal remodeling after initial stimulation and discontinuation may explain the diminishing effect of vagal stimulation on weight loss over time. This phenomenon may have affected both the centrally mediated appetite suppression and the peripherally mediated throat irritation. Our findings and findings from prior reports where the weight loss was not sustained 1 year after implantation may be explained by the theory that surgical interruption of the vagus nerve is usually associated with some degree of remodeling that can result in reformation of afferent but not efferent pathways, contributing to the observed effect [22] . However, the exact physiological basis remains elusive. Interestingly, the effect on seizure control remained positive following the reintroduction of stimulation.
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ACCEPTED MANUSCRIPT 10 We attempted to provide potential explanations for the observed weight loss. We carefully analyzed potential confounding factors for the observed weight trends.
Our patient experienced a significant adverse effect of throat irritation within 3 months of VNS implantation. The initial period of throat irritation coincided with the period of weight loss. The mechanism for the commonly reported side effects such as coughing, voice alteration, and throat irritation is related to adduction of the left vocal fold induced by the stimulation of the left vagus nerve. These side effects are typically transient, occurring during the initial calibrating period and tend to decrease with adjustments of device parameters or patient acclimation [23, 24] . Besides the throat irritation factor, no Though it cannot be definitively ruled out as a contributing factor, patient's clinical profile remained stable with regards to this aspect, with chronic immunosuppression on low dose steroids and unchanged levothyroxine supplementation, during the time period of VNS implication.
CONCLUSIONS
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VNS for intractable epilepsy has been associated with weight loss and decreased appetite; and the stimulation parameters may moderate the effect on weight loss. To our knowledge, our case is a unique report of the development of desensitization to the initial effect on appetite and throat irritation ultimately leading to weight loss from VNS, after a period of cessation of stimulation and subsequent reintroduction, with no effect on seizure control. We hypothesize that short-term cessation of VNS may allow remodeling of the vagus nerve and development of desensitization to electrical stimulation possibly limited to selective effects of VNS on the brain. This plasticity of the vagus nerve may be important in the long-term successful management of epilepsy through VNS and may impact the potential use of VNS in other neurologic conditions such as cluster headaches, stroke rehabilitation, and tinnitus [25] .
Because of the significant variability in VNS-reported changes in appetite, food cravings, and weight loss, systematic research is needed to elucidate this relationship.
Despite inconsistencies in reporting and the unknown reasons for these inconsistencies, the use of neuromodulation of the vagus nerve for obesity management is currently being reinvestigated and appears to be promising in specific individuals. 
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